13 completed, 3 unknown, 2 terminated, 1 recruiting. 19 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 13, Unknown 3, Terminated 2, Recruiting 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
Follow Recurrent Small Cell Lung Cancer: new trials by email Literature Review of Recurrent Small Cell Lung Cancer trials Research Report on Recurrent Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC Stenoparib/Temozolomide, Lurbinectedin - Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | VA Office of Research and Development | 166 | 2026-02-23 | 2026-03-11 |
| The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer SBRT, Toripalimab, Niraparib - Recurrent Small Cell Lung Cancer | Phase 2 | Unknown | Wuhan University | 57 | 2022-06-01 | 2022-05-02 |
| Anlotinib in Treatment of Recurrent Small Cell Lung Cancer Anlotinib - Recurrent Small Cell Lung Cancer | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 43 | 2018-11-01 | 2018-11-07 |
| Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Ponatinib - Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer | Phase 2 | Completed | University of Colorado, Denver | 171 | 2013-09-24 | 2022-02-11 |
| Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer Rovalpituzumab tesirine (SC16LD6.5) - Recurrent Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Stemcentrx | 82 | 2013-07-01 | 2018-08-09 |
| Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer topotecan hydrochloride, cyclodextrin-based polymer-camptothecin CRLX101 - Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 2 | Terminated | University of Chicago | 29 | 2013-01-16 | 2020-06-26 |
| S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer ziv-aflibercept, topotecan hydrochloride - Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 189 | 2009-05-01 | 2017-08-21 |
| R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer R-(-)-gossypol acetic acid, pharmacological study, laboratory biomarker analysis - Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 15 | 2008-11-01 | 2014-05-12 |
| AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer saracatinib - Extensive Stage Small Cell Lung Cancer, Lung Metastases | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2007-11-01 | 2017-12-07 |
| Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors obatoclax mesylate, topotecan hydrochloride, laboratory biomarker analysis - Recurrent Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2007-08-01 | 2015-05-05 |
| Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer dasatinib - Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 44 | 2007-04-01 | 2015-05-05 |
| Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer sorafenib tosylate - Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 89 | 2005-07-01 | 2014-05-21 |
| 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer topotecan hydrochloride, 7-hydroxystaurosporine - Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2005-01-01 | 2018-07-23 |
| Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer romidepsin, laboratory biomarker analysis - Recurrent Small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 2004-05-01 | 2014-04-10 |
| Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy becatecarin - Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 21 | 2004-04-01 | 2014-05-23 |
| Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer imatinib mesylate, laboratory biomarker analysis - Recurrent Small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 91 | 2003-05-01 | 2013-10-08 |
| Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer oblimersen sodium, carboplatin, etoposide - Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2003-04-01 | 2013-01-14 |
| Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC) Bendamustin/Ribomustin - Recurrent Small Cell Lung Cancer | Phase 2 | Unknown | Charite University, Berlin, Germany | 50 | 2001-02-01 | 2006-04-27 |
| FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer FR901228 - Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 2000-06-01 | 2024-03-04 |
Small Cell Lung Carcinoma (19) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Neoplasms (2) · Adenocarcinoma of Lung (1) · Genetic Diseases, Inborn (1) · Pleural Effusion, Malignant (1)
Bronchial Neoplasms (19) · Carcinoma, Bronchogenic (19) · Lung Diseases (19) · Neoplasms by Site (19) · Respiratory Tract Diseases (19) · Respiratory Tract Neoplasms (19) · Thoracic Neoplasms (19) · Lung Neoplasms (17) · Neoplasms (17) · Adenocarcinoma (1) · Carcinoma (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Pleural Diseases (1)
Topotecan (4) · trioctyl phosphine oxide (4) · romidepsin (2) · 7-hydroxystaurosporine (1) · Bendamustine Hydrochloride (1) · Carboplatin (1) · Dasatinib (1) · Etoposide (1) · IT-101 (1) · Imatinib Mesylate (1) · PM 01183 (1) · Sorafenib (1) · Temozolomide (1) · aflibercept (1) · anlotinib (1)
National Cancer Institute (NCI) (12) · Charite University, Berlin, Germany (1) · Peking University Cancer Hospital & Institute (1) · Stemcentrx (1) · University of Chicago (1) · University of Colorado, Denver (1) · VA Office of Research and Development (1) · Wuhan University (1)
United States (15) · Canada (1) · China (1) · Germany (1)
Ravi Salgia (2) · Afshin Dowlati (1) · Alex Adjei (1) · Antonius Miller (1) · Barbara Gitlitz (1) · David S. Schrump (1) · Donald Strickland, MD (1) · Glennwood Goss (1) · Gregory Otterson (1) · Jeffrey Allen (1) · Jian Fang (1) · Julian Molina (1) · Lee Krug (1) · Maria Baggstrom (1) · Ross D Camidge, MD, PhD (1)
PMID 25490004, PMID 21620511, PMID 25002722, PMID 27932068
U10CA031946 (3), P30CA014236 (2), U10CA025224 (2), N01CM62203 (1), N01CM62205 (1), N01CM62209 (1), P30CA015083 (1), P30CA043703 (1), U01CA062502 (1), U10CA032102 (1)